Special warnings and precautions for use:¹
Haemorrhage risk: as with other anticoagulants, patients taking Eliquis are to be carefully observed for signs of bleeding. Eliquis administration should be discontinued if severe haemorrhage occurs. 
Interaction with other medicinal products affecting haemostasis: Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated. The concomitant use of Eliquis with antiplatelet agents increases the risk of bleeding. Care is to be taken if patients are treated concomitantly with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid. Following surgery, other platelet aggregation inhibitors are not recommended concomitantly with Eliquis. In patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the potential risks should be made before combining this therapy with Eliquis.
Use of Thrombolytic agents for the treatment of acute ischemic stroke: There is very limited experience with the use of thrombolytic agents for the treatment of acute ischemic stroke in patients administered apixaban.

Adverse Reactions:¹
Common adverse reactions include: nausea, anemia, thrombocytopenia, epistaxis, contusion, haematuria, hemorrhage, haematoma, hypotension (including procedural hypotension), eye haemorrhage, mouth haemorrhage, rectal haemorrhage, gingival bleeding and gastrointestinal haemorrhage, gamma-glutamyltransferase increased, alanine aminotransferase increased, skin rash, abnormal vaginal haemorrhage, urogenital haemorrhage.